Michael Duruisseaux: Prognostic value of neutrophil to lymphocyte ratio before adjuvant durvalumab in locally advanced NSCLC
Michael Duruisseaux, Thoracic Oncologist and Deputy Director at HCL – University Hospital of Lyon, shared on X:
“Hot of the press: Prognostic value of neutrophil to lymphocyte ratio and lymphocyte counts before durvalumab consolidation after radio-chemotherapy in locally advanced non-small cell lung cancer.”
Authors: Arnaud Colomb,Benoit Allignet, Mehdi Lamkhioued, Aurelie Swalduz, Lionel Falchero, Aurélie Kienlen, Michaël Duruisseaux, Coralie Moncharmont
Dr. , Michael Duruisseaux coordinates the general and orphan thoracic oncology team in the pneumology department at Louis Pradel Hospital (Hospices Civils de Lyon) and serves as the medical director of the Joint Research Unit in Thoracic Oncology. He is also a physician-scientist in the OncoPharmacology team at the Lyon Cancer Research Center, where he leads a research group focused on thoracic oncology and pharmacology.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023